Evidence map›Paper›PMID 26632528›Full record

ArticlePhytochemistry2016

Kalkipyrone B, a marine cyanobacterial γ-pyrone possessing cytotoxic and anti-fungal activities.

Matthew J Bertin, Ozlem Demirkiran, Gabriel Navarro, Nathan A Moss, John Lee, Gregory M Goldgof, Edgar Vigil, Elizabeth A Winzeler, Fred A Valeriote, William H Gerwick

Abstract read
In one paragraph

Article in Phytochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthew J BertinCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, 8615 Kennel Way, La Jolla, CA 92037, United States.
Ozlem DemirkiranDepartment of Pharmacognosy, Faculty of Pharmacy, Trakya University, Edirne 22030, Turkey.
Gabriel NavarroCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, 8615 Kennel Way, La Jolla, CA 92037, United States.
Nathan A MossCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, 8615 Kennel Way, La Jolla, CA 92037, United States.
John LeeCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, 8615 Kennel Way, La Jolla, CA 92037, United States; Chemistry & Biochemistry Program, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States.
Gregory M GoldgofDepartment of Pediatrics, University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, United States.
Edgar VigilDepartment of Pediatrics, University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, United States.
Elizabeth A WinzelerDepartment of Pediatrics, University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, United States.
Fred A ValerioteHenry Ford Health System, Department of Internal Medicine, Josephine Ford Cancer Center, 440 Burroughs, Room 415, Detroit, MI 48202, United States.
William H GerwickCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, 8615 Kennel Way, La Jolla, CA 92037, United States; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. Electronic address: wgerwick@ucsd.edu.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007198 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHI, NEIL C, INSEL, PAUL A · 1985 to 2024
$29.3M
ICBG: "Training, Conservation and Drug Discovery using Panamanian MicroorganismsU01TW006634 · FIC · SMITHSONIAN INSTITUTION · PI GERWICK, WILLIAM HENRY · 2003 to 2013
$7.8M
Discovery of Anticancer Drugs from CyanophytesR01CA100851 · NCI · HENRY FORD HEALTH SYSTEM · PI VALERIOTE, FREDERICK AUGUSTUS · 2004 to 2013
$3.8M
Defining the targets of broad intervention antimalarial agentsR01AI103058 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2013 to 2016
$2.6M
Training Program in Marine BiotechnologyT32GM067550 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GERWICK, WILLIAM HENRY · 2004 to 2019
$2.0M
FIC NIH HHS TW006634FIC NIH HHS U01 TW006634NCI NIH HHS CA100851NCI NIH HHS R01 CA100851NIAID NIH HHS R01 AI103058NIGMS NIH HHS T32 GM007198NIGMS NIH HHS T32 GM067550
6 · The paper itself

Abstract

Bioassay-guided fractionation of two marine cyanobacterial extracts using the H-460 human lung cancer cell line and the OVC-5 human ovarian cancer cell line led to the isolation of three related α-methoxy-β, β'-dimethyl-γ-pyrones each containing a modified alkyl chain, one of which was identified as the previously reported kalkipyrone and designated kalkipyrone A. The second compound was an analog designated kalkipyrone B. The third was identified as the recently reported yoshinone A, also isolated from a marine cyanobacterium. Kalkipyrone A and B were obtained from a field-collection of the cyanobacterium Leptolyngbya sp. from Fagasa Bay, American Samoa, while yoshinone A was isolated from a field-collection of cyanobacteria (cf. Schizothrix sp.) from Panama. One-dimensional and two-dimensional NMR experiments were used to determine the overall structures and relative configurations of the kalkipyrones, and the absolute configuration of kalkipyrone B was determined by (1)H NMR analysis of diastereomeric Mosher's esters. Kalkipyrone A showed good cytotoxicity to H-460 human lung cancer cells (EC50=0.9μM), while kalkipyrone B and yoshinone A were less active (EC50=9.0μM and >10μM, respectively). Both kalkipyrone A and B showed moderate toxicity to Saccharomyces cerevisiae ABC16-Monster strain (IC50=14.6 and 13.4μM, respectively), whereas yoshinone A was of low toxicity to this yeast strain (IC50=63.8μM).

Indexed as

Antineoplastic AgentsCyanobacteriaDrug Screening Assays, AntitumorFemaleHumansMarine BiologyMolecular StructurePanamaPyronesAntineoplastic Agentskalkipyrone Akalkipyrone BPyronesCyanobacteriaKalkipyroneLeptolyngbyaMooreaPolyketideSchizothrixYoshinone

Identifiers

PMID26632528
PMCPMC4724546

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.